Back to Search
Start Over
Lung cancer and immunotherapy: a real-life experience from second line and beyond.
- Source :
-
Future oncology (London, England) [Future Oncol] 2019 Sep; Vol. 15 (26), pp. 3025-3032. Date of Electronic Publication: 2019 Aug 19. - Publication Year :
- 2019
-
Abstract
- Aim: This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Materials & methods: Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. Results: One hundred and ten patients were included with PD-L1 expression above 50%, between 1-49 and <1% in 38.6, 27.3 and 34.1% of patients, respectively. Checkpoint inhibitors were used as second, third and fourth line in 74.7, 21.8 and 3.5%, respectively. Partial response was observed in 25.6% of patients. Median progression-free survival was 4 months and median overall survival was 8.1 months. Conclusion: Immunotherapies are emerging as important tools in the oncologic field with good responses in real-life practice.
- Subjects :
- Aged
Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological adverse effects
B7-H1 Antigen antagonists & inhibitors
Biomarkers, Tumor
Female
Humans
Lung Neoplasms mortality
Lung Neoplasms pathology
Male
Middle Aged
Prognosis
Retreatment
T-Lymphocyte Subsets drug effects
T-Lymphocyte Subsets immunology
T-Lymphocyte Subsets metabolism
Treatment Outcome
Antineoplastic Agents, Immunological therapeutic use
Immunotherapy adverse effects
Immunotherapy methods
Lung Neoplasms drug therapy
Lung Neoplasms immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 15
- Issue :
- 26
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 31424958
- Full Text :
- https://doi.org/10.2217/fon-2019-0144